Recent studies have shown that PKCα functionally acquired mutation (M489V) accelerates synaptic loss, reduces dendritic spine density, and cognitive decline in Alzheimer's disease (AD) model mice, and inhibition of PKCα activity emerges as a potential therapeutic strategy [53]. The gene discussed is PRKCA; the disease is early-onset autosomal dominant Alzheimer disease.